FM SEPTEMBER 2018 ISSUE - digital edition

devices&gadgets
WebCardio to be rolled out
pan India by Dec
Kochi-based GadgEon Smart Systems
Pvt Ltd will launch its wireless multiday
holter, WebCardio, across India by
December. The IoT-based wireless holter
can continuously record ECG up to three
days. This innovative solution developed
by GadgEon using a biosensor platform
has already gone through clinical validation
and currently launched only in selected
markets.
“We are currently present in Kerala and
a few cities in other states. As the product
is well received in these markets, we are
planning to take it nationwide in another 3
to 4 months,” said Hariprasad V Nair, Chief
Executive Officer, GadgEon Systems Inc,
the US-based parent of GadgEon Smart
Systems.
Explaining the advantages of
WebCardio, Aravind Ravikumar, Director-
Healthcare & Biomedical, GadgEon Smart
Systems, said that the nurse or technician
can view the ECG waveform after affixing
the ECG patch on patient, by wirelessly
pairing it with a companion mobile App.
This helps technician to ascertain the
quality of ECG before starting the holter
recording process. Once recording is
initiated, the patient can go
home and continue with their
normal activities. While,
its “Pay per Use model”
allows smaller clinics and
individual doctors to add
Holter monitoring to their
practice without any
capital investment.
“For the hospitals,
that already has
holter recorder,
WebCardio
would help
augmenting the
capacity without
any additional
Hariprasad V Nair and
Aravind Ravikumar
investment.” he
added.
Zephyr Valve to
treat severe
emphysema
Zephyr Endobronchial
Valve to treat breathing
difficulty associated with severe
emphysema received clearance in
the US.
The device is a less-invasive
treatment option for people
with emphysema who have
severe symptoms that have not
improved from taking medicines.
Zephyr Valves are similar in
size to pencil erasers. Doctors
can place them into the diseased
areas of the lung airways during
a procedure using a flexible
bronchoscope in a hospital
setting.
The design of the device is
intended to prevent air from
entering the damaged parts of
the lung and to allow trapped
air and fluids to escape. During
inhalation, the valves close,
preventing air from entering the
damaged part of the lung. During
Magnetic device for guiding sentinel node biopsies
The Magtrace and Sentimag
magnetic localization system
for guiding lymph node biopsies
in patients with breast cancer
undergoing mastectomy has received
marketing approval in the US.
The device uses magnetic
detection during sentinel
lymph node biopsy
procedures to identify
specific lymph nodes,
known as sentinel lymph
nodes, for surgical removal.
Testing the sentinel lymph
nodes indicates whether
the cancer has spread from
the breast.
The Sentimag System comprises a
sensitive magnetic sensing probe and
a base unit designed to detect small
amounts of Magtrace, the magnetic
tracer drug that is injected into breast
tissue.
The Magtrace particles travel to
lymph nodes and become physically
trapped in them, facilitating
magnetic detection of the lymph
nodes.
Following the injection of
Magtrace, the Sentimag probe is
applied to the patients’ skin in
areas closest to the tumour site
containing the lymph nodes.
The sensing of the magnetic
particles is indicated by changes in
audio and visual alerts from the base
unit, enabling the surgeon to move
the hand-held probe around the area
of the lymph nodes, and locate the
sentinel lymph node or nodes.
Currently, a sentinel lymph node
biopsy is performed after injection
of radioactive materials and/or blue
dye. This magnetic system will offer
an option for patients undergoing
mastectomy for their sentinel lymph
biopsy procedure that does not
require the injection of radioactive
materials.
The device is manufactured by
Endomagnetics Inc.
88 / FUTURE MEDICINE / SEPTEMBER 2018